Table 1 Demographics and Clinical Characteristics of the patients in the development and validation cohorts
|  | development cohort (n = 392) | validation cohort (n = 178) |
|---|---|---|
Demographics | ||
 Age, y, median (IQR) | 70(60–79) | 72(61–81) |
 Age > 60 y, n (%) | 287(73.2) | 136(76.4) |
 Male sex, n (%) | 236(60.2) | 102(57.3) |
Medical history, n (%) | ||
 Hypertension | 288(73.5) | 131(73.6) |
 Diabetes mellitus | 125(31.9) | 62(34.8) |
 Previous stroke | 53(13.5) | 50(28.1) |
 Atrial fibrillation | 80(20.9) | 36(20.2) |
 Antiplatelet | 53(13.5) | 48(27.0) |
 Oral anticoagulant | 13(3.3) | 21(11.8) |
 Smoking current | 147(37.5) | 62(34.8) |
Baseline data, median (IQR) | ||
 Systolic BP, mm Hg, | 153(137–171) | 157(138–175) |
 Diastolic BP, mm Hg, | 88(80–99) | 88(77–99) |
 Temperature,°C | 36.5(36.4–36.7) | 36.5(36.2–36.7) |
 Glucose, mmol/L | 6.32(5.15–8.31) | 7.47(6.15–9.59) |
 Total cholesterol (TC), mmol/L | 4.78(4.06–5.45) | 4.81(4.08–5.58) |
 Triglyceride (TG), mmol/L | 1.33(1.01–1.88) | 1.51(1.06–2.33) |
 High-density lipoprotein (HDL), mmol/L | 1.06(0.91–1.25) | 1.39(1.14–1.65) |
 Low-density lipoprotein (LDL), mmol/L | 2.90(2.20–3.51) | 2.76(2.17–3.31) |
 Blood platelet (PLT), × 109/L | 179.00(135.25–215.75) | 194.00(154.75–226.50) |
 Prothrombin time (PT)% | 99.00(90.00–109.00) | 91.64(81.34–101.97) |
 APTT, s | 35.20(32.40–37.88) | 28.40(26.00–30.53) |
 INR | 1.00(0.95–1.07) | 1.04(0.99–1.10) |
 Fibrous Protein (Fib), g/L | 3.29(2.84–3.94) | 3.04(2.57–3.52) |
Imaging data, median (IQR) | ||
 Cerebral Infarction Area (CIA), cm2 | 3.00(1.00–9.69) | 3.16(0.99–19.09) |
 Cerebral Infarction Volume (CIV), cm3 | 3.87(0.78–19.31) | 3.78(0.72–43.28) |
Scores | ||
 THRIVE score, median (IQR) | 2.00(2.00–3.75) | 3.00(2.00–4.00) |
 NIHSS score, median (IQR) | 5(3–9) | 6 (4–16) |
 NIHSS score > 20, n (%) | 11(2.8) | 22(12.7) |
Treament | ||
 onset-to-treatment (OTT), h, median (IQR) | 13.50(5.00–48.00) | 7.00(2.00–24.00) |
 Thrombolysis or ET, n (%) | 21(5.4) | 32(18.5) |